Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis

ConclusionThe study showed long-term suppression of TRACP-5b and BAP levels and sustaining BMD after denosumab administration over an extended period in patients undergoing hemodialysis.

Source: Journal of Bone and Mineral Metabolism - March 21, 2024 Category: Orthopaedics Source Type: research